Addressing Obesity During Psoriasis Patient Consultations - Takeaways - MDSpire

Addressing Obesity During Psoriasis Patient Consultations

  • By

  • Joana Nicolau

  • Anna López-Ferrer

  • Pablo de la Cueva

  • February 2, 2026

  • 0 min

Share

  • 1

    Up to 50% of psoriasis patients are obese, which increases cardiovascular risk and reduces the efficacy of biologic treatments.

  • 2

    No specific guidelines exist for managing obesity in psoriasis patients, despite its significant impact on treatment outcomes.

  • 3

    GLP-1 receptor agonists and tirzepatide can lead to weight loss and improved metabolic health, potentially reducing psoriasis severity.

  • 4

    A multidisciplinary, patient-centered approach is essential for optimizing dermatological, metabolic, and cardiovascular outcomes in these patients.

  • 5

    Dermatologists should actively assess and manage obesity in psoriasis patients to improve overall health and treatment responses.

Original Source(s)

Addressing Obesity During Psoriasis Patient Consultations

  • by Joana Nicolau, Anna López-Ferrer, Pablo de la Cueva

  • February 2, 2026

Related Content

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Case Report: rapid progressive puberty in siblings with MC4R p. Arg165Gln: longitudinal follow-up and gonadotropin-releasing hormone agonist treatment